Petrova Penka 4
4 · Trillium Therapeutics Inc. · Filed Feb 10, 2021
Insider Transaction Report
Form 4
Petrova Penka
Chief Development Officer
Transactions
- Exercise/Conversion
Common Shares
2021-02-08$3.31/sh+2,604$8,629→ 5,312 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-08−2,604→ 54,688 totalExercise: $3.31Exp: 2028-11-08→ Common Shares (2,604 underlying) - Exercise/Conversion
Common Shares
2021-02-08$0.30/sh+2,708$806→ 2,708 total - Sale
Common Shares
2021-02-08$12.65/sh−5,312$67,197→ 0 total - Exercise/Conversion
Common Shares
2021-02-09$9.62/sh+508$4,888→ 508 total - Sale
Common Shares
2021-02-09$14.17/sh−508$7,200→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-08−2,708→ 89,376 totalExercise: $0.30Exp: 2029-11-07→ Common Shares (2,708 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-09−508→ 4,574 totalExercise: $9.62Exp: 2027-11-09→ Common Shares (508 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7834 USD.
- [F3]The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7834 USD.
- [F4]The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7873 USD.
- [F5]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.